Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well tolerated and
shows superiority over active control for the prevention of chemotherapy-induced nausea and vomiting during the
5-day (0–120 h) at-risk period after administration of moderately emetogenic chemotherapy or regimens containing
an anthracycline and cyclophosphamide.